History
  • No items yet
midpage
Primo v. Pacific Biosciences of California, Inc.
940 F. Supp. 2d 1105
N.D. Cal.
2013
Read the full case

Background

  • Putative securities class action against PacBio, officer/director, and underwriter defendants for alleged §11, §12(a)(2), §15, and §10(b)/§20(a) violations based on IPO materials and post-IPO disclosures.
  • Plaintiffs allege PacBio RS technology had undisclosed defects and misrepresentations regarding accuracy, upgrades, and future applications.
  • IPO occurred October 27, 2010, raising $230 million; PacBio disclosed technology and performance expectations in offering materials.
  • Aug. 4–5, 2011 disclosures and JP Morgan downgrade allegedly revealed limitations; stock price dropped.
  • September 20, 2011 layoff announcement further affected stock and R&D functions; class period through September 20, 2011.
  • Court grants motions to dismiss 1AC with leave to amend; standing and pleading standards applied to multiple claims, with some claims to be repleaded.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Puzzle pleading improper under Rule 8 Powell/1AC failure to connect omissions to specific statements Defendants say 1AC is a puzzle pleading. Granted; puzzle pleading improper.
§11 misrepresentation/omission in registration statement Misstatements/omissions material and actionable No misstatement/omission plead sufficiently. Granted; §11 claim dismissed with leave to amend.
§12(a)(2) standing and misrepresentation/omission in prospectus Powell has aftermarket standing; Primo lacks standing Aftermarket standing uncertain; proper privity required Granted; §12(a)(2) claim dismissed; leave to amend with standing showings.
§10(b)/Rule 10b-5 pleading and scienter Allegations sufficient against PacBio and officers Insufficient scienter and misleading statements Granted; §10(b) claim dismissed against officer Defendants (except Martin) and PacBio; leave to amend.
Control person liability §15/§20(a) against officers/directors Alleged controlling persons; underlying primary violation present No sufficiently pled primary violation Granted; §15 and §20(a) claims dismissed with leave to re-assert if primary violations pled.

Key Cases Cited

  • In re Stac Elecs. Sec. Litig., 89 F.3d 1399 (9th Cir. 1996) (§11/section pleading standard; materiality and omissions)
  • Gustafson v. Alloyd Co., Inc., 513 U.S. 564 (U.S. 1995) (Section 12(2) liability requires privity with offering)
  • Twombly, Bell Atl. Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) (Pleading standards; plausibility required)
  • Ashcroft v. Iqbal, 556 U.S. 662 (U.S. 2009) (Plausibility/applications of Rule 8; Rule 9(b) where appropriate)
  • Rubke v. Capitol Bancorp, Ltd. Sec. Litig., 551 F.3d 1156 (9th Cir. 2009) (Separate Securities Act pleadings; Rule 9(b) distinctions)
  • Pinter v. Dahl, 486 U.S. 622 (U.S. 1988) (Section 12 liability; seller definition and privity)
Read the full case

Case Details

Case Name: Primo v. Pacific Biosciences of California, Inc.
Court Name: District Court, N.D. California
Date Published: Apr 15, 2013
Citation: 940 F. Supp. 2d 1105
Docket Number: No. C 11-6599 CW
Court Abbreviation: N.D. Cal.